f848b6f13c5f10ae45dde9209034d779 338239.pdf 9e751f5b057eadbc97034c538e7b00aaf226b6e1 338239.pdf b693e6f84b667c21dc9254cb834a460b26941f5c70e5b9d53c01ecde674521f2 338239.pdf Title: Real-World Data on the Efficacy and Safety of Osilodrostat in Patients with Cushing’s Disease in Spain Subject: Objective: To evaluate the efficacy and safety of osilodrostat in patients with Cushing’s disease (CD). Methods: A retrospective, multicenter, real-world study of patients with CD. The main efficacy endpoint was the proportion of patients who were complete responders (urinary free cortisol [UFC] < the upper limit of normal and/or with adrenal insufficiency development). Results: Thirty-seven CD patients were enrolled. There were 33 patients who initially received osilodrostat in monotherapy and 4 in combination. However, 3 patients of the monotherapy group were switched to combination therapy. The median duration of osilodrostat treatment was 5 months (range 1–93). All the patients were classified as responders: 33 (89.2%) had complete response and 4 partial response. A positive correlation was detected between the percentage of UFC decrease and the maximum (r = 0.481, p = 0.006) and the maintenance doses (r = 0.440, p = 0.011). The initial doses of osilodrostat were a predictor of complete response (vs. partial) (Odds ratio [OR] 2.82, p = 0.030). The median time to UFC normalization in the group of complete responders was 4 weeks (range 1–20) and UFC normalized before or at month 1 in 67% (n = 20/30) of the patients. Osilodrostat led to a significant decrease in systolic and diastolic blood pressure in parallel with a reduction of antihypertensive medications. Conclusions: Osilodrostat leads to a complete UFC normalization in up to 90% of the patients with CD, in parallel with an improvement in the cardiometabolic profile. A proper titration of osilodrostat is important to achieve a complete response since a positive correlation between the doses and the UFC reduction was observed. Keywords: Cushing’s syndrome; Cushing’s disease; pituitary; osilodrostat; urinary free cortisol Author: Marta Araujo-Castro, Rogelio García-Centeno, Laura González, Felicia A. Hanzu, Aida Orois, Rosa Camara, María Dolores Ollero García, Ana Irigaray Echarri, Paola Gracia Gimeno, Eider Pascual-Corrales, Betina Biagetti, Andrés Cardona, Inmaculada González Molero, Andreu Simo-Servat, Fernando Guerrero Pérez, Rocío Villar-Taibo, Ignacio Bernabéu, Carmen Fajardo-Montañana, Cristina Novo-Rodríguez, Carmen Tenorio Jimenéz, María Calatayud, María Dolores Moure Rodríguez, Fernando Cordido, Ana Castro, Lucía Manzano Valero, Miguel Paja Fano, Jessica Goi, Anna Aulinas, Pablo Abellán, Pedro Iglesias and Alfonso Soto-Moreno Creator: LaTeX with hyperref Producer: pdfTeX-1.40.25; modified using OpenPDF 1.4.2 CreationDate: Mon Oct 27 10:30:30 2025 CET ModDate: Mon Oct 27 10:32:55 2025 CET Custom Metadata: yes Metadata Stream: no Tagged: no UserProperties: no Suspects: no Form: none JavaScript: no Pages: 13 Encrypted: no Page size: 595.276 x 841.89 pts (A4) Page rot: 0 File size: 1385189 bytes Optimized: no PDF version: 1.7 name type encoding emb sub uni object ID ------------------------------------ ----------------- ---------------- --- --- --- --------- WRZUAW+URWPalladioL-Roma Type 1 Custom yes yes yes 108 0 NQUCLN+URWPalladioL-Ital Type 1 Custom yes yes yes 109 0 QVMLOU+URWPalladioL-Bold Type 1 Custom yes yes yes 110 0 CAMXTK+EURM10 Type 1 Builtin yes yes yes 185 0 SKVKGL+CMSY10 Type 1 Builtin yes yes yes 210 0 JEFNLC+PalatinoLinotype,BoldItalic TrueType WinAnsi yes yes no 152 0 JEFLPG+PalatinoLinotype TrueType WinAnsi yes yes no 153 0 QLBIEB+URWPalladioL-BoldItal Type 1 Custom yes yes yes 309 0 XIRVNA+EURB10 Type 1 Builtin yes yes yes 310 0 IYLPED+CMBSY10 Type 1 Builtin yes yes yes 311 0 JEFLPG+PalatinoLinotype TrueType WinAnsi yes yes no 285 0 JEFLPE+PalatinoLinotype,Bold TrueType WinAnsi yes yes no 286 0 JEFPJK+Arial TrueType WinAnsi yes yes no 287 0 JEFNLC+PalatinoLinotype,BoldItalic TrueType WinAnsi yes yes no 336 0 JEFLPG+PalatinoLinotype TrueType WinAnsi yes yes no 337 0 JEFLPE+PalatinoLinotype,Bold TrueType WinAnsi yes yes no 338 0 JEFLPG+PalatinoLinotype TrueType WinAnsi yes yes no 407 0 JMGJIR+VnURWPalladioL Type 1 Custom yes yes yes 698 0 Jhove (Rel. 1.28.0, 2023-05-18) Date: 2026-11-06 04:28:09 CET RepresentationInformation: 338239.pdf ReportingModule: PDF-hul, Rel. 1.12.4 (2023-03-16) LastModified: 2026-11-05 17:33:03 CET Size: 1385189 Format: PDF Version: 1.7 Status: Well-Formed and valid SignatureMatches: PDF-hul MIMEtype: application/pdf PDFMetadata: Objects: 732 FreeObjects: 1 IncrementalUpdates: 0 DocumentCatalog: ViewerPreferences: HideToolbar: false HideMenubar: false HideWindowUI: false FitWindow: true CenterWindow: false DisplayDocTitle: false NonFullScreenPageMode: UseNone Direction: L2R ViewArea: CropBox ViewClip: CropBox PrintArea: CropBox PageClip: CropBox PageLayout: SinglePage PageMode: UseNone Outlines: Item: Title: Introduction Item: Title: Materials and Methods Children: Item: Title: Study Design and Definitions Item: Title: Primary and Secondary Outcomes Item: Title: Variables and Hormonal Assays Item: Title: Statistical Analysis Item: Title: Results Children: Item: Title: Baseline Characteristics Item: Title: Osilodrostat Treatment: Efficacy and Safety Item: Title: Osilodrostat Treatment: Impact on the Control of Cardiometabolic Comorbidities Item: Title: Discussion Item: Title: Conclusions Item: Title: References Info: Title: Real-World Data on the Efficacy and Safety of Osilodrostat in Patients with Cushing’s Disease in Spain Author: Marta Araujo-Castro, Rogelio García-Centeno, Laura González, Felicia A. Hanzu, Aida Orois, Rosa Camara, María Dolores Ollero García, Ana Irigaray Echarri, Paola Gracia Gimeno, Eider Pascual-Corrales, Betina Biagetti, Andrés Cardona, Inmaculada González Molero, Andreu Simo-Servat, Fernando Guerrero Pérez, Rocío Villar-Taibo, Ignacio Bernabéu, Carmen Fajardo-Montañana, Cristina Novo-Rodríguez, Carmen Tenorio Jimenéz, María Calatayud, María Dolores Moure Rodríguez, Fernando Cordido, Ana Castro, Lucía Manzano Valero, Miguel Paja Fano, Jessica Goi, Anna Aulinas, Pablo Abellán, Pedro Iglesias and Alfonso Soto-Moreno Subject: Objective: To evaluate the efficacy and safety of osilodrostat in patients with Cushing’s disease (CD). Methods: A retrospective, multicenter, real-world study of patients with CD. The main efficacy endpoint was the proportion of patients who were complete responders (urinary free cortisol [UFC] < the upper limit of normal and/or with adrenal insufficiency development). Results: Thirty-seven CD patients were enrolled. There were 33 patients who initially received osilodrostat in monotherapy and 4 in combination. However, 3 patients of the monotherapy group were switched to combination therapy. The median duration of osilodrostat treatment was 5 months (range 1–93). All the patients were classified as responders: 33 (89.2%) had complete response and 4 partial response. A positive correlation was detected between the percentage of UFC decrease and the maximum (r = 0.481, p = 0.006) and the maintenance doses (r = 0.440, p = 0.011). The initial doses of osilodrostat were a predictor of complete response (vs. partial) (Odds ratio [OR] 2.82, p = 0.030). The median time to UFC normalization in the group of complete responders was 4 weeks (range 1–20) and UFC normalized before or at month 1 in 67% (n = 20/30) of the patients. Osilodrostat led to a significant decrease in systolic and diastolic blood pressure in parallel with a reduction of antihypertensive medications. Conclusions: Osilodrostat leads to a complete UFC normalization in up to 90% of the patients with CD, in parallel with an improvement in the cardiometabolic profile. A proper titration of osilodrostat is important to achieve a complete response since a positive correlation between the doses and the UFC reduction was observed. Keywords: Cushing’s syndrome; Cushing’s disease; pituitary; osilodrostat; urinary free cortisol Creator: LaTeX with hyperref Producer: pdfTeX-1.40.25; modified using OpenPDF 1.4.2 CreationDate: Mon Oct 27 10:30:30 CET 2025 ModDate: Mon Oct 27 10:32:55 CET 2025 ID: 0x8baddfccbc9fb18d1141d083d3efbdbd, 0x951524bceade3a073ed4a9b2bb3f9456 Filters: FilterPipeline: FlateDecode Fonts: Type1: Font: BaseFont: SKVKGL+CMSY10 FontSubset: true FirstChar: 2 LastChar: 21 FontDescriptor: FontName: SKVKGL+CMSY10 Flags: Symbolic FontBBox: -29, -960, 1116, 775 FontFile: true ToUnicode: true Font: BaseFont: QLBIEB+URWPalladioL-BoldItal FontSubset: true FirstChar: 110 LastChar: 112 FontDescriptor: FontName: QLBIEB+URWPalladioL-BoldItal Flags: Symbolic FontBBox: -170, -300, 1073, 935 FontFile: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: XIRVNA+EURB10 FontSubset: true FirstChar: 22 LastChar: 22 FontDescriptor: FontName: XIRVNA+EURB10 Flags: Symbolic FontBBox: -30, -247, 1178, 723 FontFile: true ToUnicode: true Font: BaseFont: IYLPED+CMBSY10 FontSubset: true FirstChar: 2 LastChar: 2 FontDescriptor: FontName: IYLPED+CMBSY10 Flags: Symbolic FontBBox: -26, -940, 1332, 825 FontFile: true ToUnicode: true Font: BaseFont: CAMXTK+EURM10 FontSubset: true FirstChar: 12 LastChar: 22 FontDescriptor: FontName: CAMXTK+EURM10 Flags: Symbolic FontBBox: -32, -243, 1060, 720 FontFile: true ToUnicode: true Font: BaseFont: JMGJIR+VnURWPalladioL FontSubset: true FirstChar: 182 LastChar: 227 FontDescriptor: FontName: JMGJIR+VnURWPalladioL Flags: Symbolic FontBBox: -166, -283, 1021, 943 FontFile: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: WRZUAW+URWPalladioL-Roma FontSubset: true FirstChar: 2 LastChar: 243 FontDescriptor: FontName: WRZUAW+URWPalladioL-Roma Flags: Symbolic FontBBox: -166, -283, 1021, 943 FontFile: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: NQUCLN+URWPalladioL-Ital FontSubset: true FirstChar: 2 LastChar: 121 FontDescriptor: FontName: NQUCLN+URWPalladioL-Ital Flags: Symbolic FontBBox: -170, -305, 1010, 941 FontFile: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: QVMLOU+URWPalladioL-Bold FontSubset: true FirstChar: 2 LastChar: 241 FontDescriptor: FontName: QVMLOU+URWPalladioL-Bold Flags: Symbolic FontBBox: -152, -301, 1000, 935 FontFile: true EncodingDictionary: Differences: true ToUnicode: true Pages: Page: Sequence: 1 Annotations: Annotation: Subtype: Link Rect: 97, 177, 152, 186 Annotation: Subtype: Link Rect: 34, 165, 102, 174 Annotation: Subtype: Link Rect: 36, 75, 152, 84 Annotation: Subtype: Link Rect: 34, 63, 89, 72 Annotation: Subtype: Link Rect: 34, 773, 179, 809 Annotation: Subtype: Link Rect: 515, 773, 560, 809 Annotation: Subtype: Link Rect: 142, 663, 153, 677 Annotation: Subtype: Link Rect: 504, 663, 515, 677 Annotation: Subtype: Link Rect: 242, 650, 253, 663 Annotation: Subtype: Link Rect: 144, 636, 155, 649 Annotation: Subtype: Link Rect: 232, 636, 243, 649 Annotation: Subtype: Link Rect: 363, 622, 374, 635 Annotation: Subtype: Link Rect: 467, 622, 478, 635 Annotation: Subtype: Link Rect: 173, 608, 184, 621 Annotation: Subtype: Link Rect: 312, 608, 323, 621 Annotation: Subtype: Link Rect: 450, 608, 461, 621 Annotation: Subtype: Link Rect: 292, 594, 303, 607 Annotation: Subtype: Link Rect: 485, 594, 496, 607 Annotation: Subtype: Link Rect: 135, 580, 146, 594 Annotation: Subtype: Link Rect: 206, 580, 217, 594 Annotation: Subtype: Link Rect: 374, 580, 385, 594 Annotation: Subtype: Link Rect: 463, 580, 474, 594 Annotation: Subtype: Link Rect: 170, 568, 181, 580 Annotation: Subtype: Link Rect: 423, 27, 560, 37 Annotation: Subtype: Link Rect: 34, 356, 87, 375 Page: Sequence: 2 Annotations: Annotation: Subtype: Link Rect: 442, 457, 449, 466 ActionDest: 60 Annotation: Subtype: Link Rect: 348, 429, 355, 438 ActionDest: 60 Annotation: Subtype: Link Rect: 427, 401, 434, 410 ActionDest: 60 Annotation: Subtype: Link Rect: 357, 345, 364, 354 ActionDest: 60 Annotation: Subtype: Link Rect: 365, 345, 372, 354 ActionDest: 60 Annotation: Subtype: Link Rect: 378, 317, 385, 326 ActionDest: 60 Annotation: Subtype: Link Rect: 511, 317, 518, 326 ActionDest: 197 Annotation: Subtype: Link Rect: 225, 303, 232, 312 ActionDest: 197 Annotation: Subtype: Link Rect: 352, 303, 359, 312 ActionDest: 197 Annotation: Subtype: Link Rect: 190, 275, 197, 284 ActionDest: 197 Annotation: Subtype: Link Rect: 198, 275, 210, 284 ActionDest: 197 Annotation: Subtype: Link Rect: 260, 275, 272, 284 ActionDest: 197 Annotation: Subtype: Link Rect: 311, 206, 323, 215 ActionDest: 197 Annotation: Subtype: Link Rect: 379, 164, 386, 173 ActionDest: 197 Annotation: Subtype: Link Rect: 386, 164, 398, 173 ActionDest: 197 Annotation: Subtype: Link Rect: 401, 164, 413, 173 ActionDest: 197 Annotation: Subtype: Link Rect: 432, 150, 444, 159 ActionDest: 197 Annotation: Subtype: Link Rect: 445, 150, 457, 159 ActionDest: 197 Annotation: Subtype: Link Rect: 279, 136, 291, 145 ActionDest: 197 Annotation: Subtype: Link Rect: 292, 136, 304, 145 ActionDest: 197 Page: Sequence: 3 Annotations: Annotation: Subtype: Link Rect: 276, 611, 283, 623 ActionDest: 15 Page: Sequence: 4 Annotations: Annotation: Subtype: Link Rect: 552, 142, 559, 154 ActionDest: 123 Page: Sequence: 5 Page: Sequence: 6 Annotations: Annotation: Subtype: Link Rect: 509, 655, 516, 667 ActionDest: 47 Page: Sequence: 7 Annotations: Annotation: Subtype: Link Rect: 306, 742, 314, 754 ActionDest: 388 Annotation: Subtype: Link Rect: 272, 703, 279, 712 ActionDest: 60 Annotation: Subtype: Link Rect: 282, 703, 294, 712 ActionDest: 197 Annotation: Subtype: Link Rect: 368, 703, 375, 712 ActionDest: 60 Annotation: Subtype: Link Rect: 378, 703, 385, 712 ActionDest: 60 Annotation: Subtype: Link Rect: 367, 275, 374, 287 ActionDest: 51 Annotation: Subtype: Link Rect: 399, 233, 406, 245 ActionDest: 51 Page: Sequence: 8 Annotations: Annotation: Subtype: Link Rect: 296, 363, 303, 375 ActionDest: 51 Annotation: Subtype: Link Rect: 354, 363, 361, 375 ActionDest: 393 Page: Sequence: 9 Page: Sequence: 10 Annotations: Annotation: Subtype: Link Rect: 493, 632, 500, 641 ActionDest: 197 Annotation: Subtype: Link Rect: 500, 632, 512, 641 ActionDest: 197 Annotation: Subtype: Link Rect: 513, 632, 525, 641 ActionDest: 197 Annotation: Subtype: Link Rect: 238, 604, 250, 613 ActionDest: 197 Annotation: Subtype: Link Rect: 315, 604, 327, 613 ActionDest: 197 Annotation: Subtype: Link Rect: 544, 534, 556, 544 ActionDest: 197 Annotation: Subtype: Link Rect: 401, 409, 413, 418 ActionDest: 197 Annotation: Subtype: Link Rect: 213, 353, 225, 363 ActionDest: 197 Annotation: Subtype: Link Rect: 496, 326, 508, 335 ActionDest: 197 Page: Sequence: 11 Annotations: Annotation: Subtype: Link Rect: 494, 577, 506, 586 ActionDest: 197 Annotation: Subtype: Link Rect: 457, 536, 469, 545 ActionDest: 197 Annotation: Subtype: Link Rect: 190, 466, 202, 475 ActionDest: 197 Annotation: Subtype: Link Rect: 270, 173, 277, 182 ActionDest: 197 Annotation: Subtype: Link Rect: 278, 174, 290, 182 ActionDest: 197 Annotation: Subtype: Link Rect: 293, 174, 305, 182 ActionDest: 197 Page: Sequence: 12 Annotations: Annotation: Subtype: Link Rect: 421, 758, 433, 767 ActionDest: 197 Annotation: Subtype: Link Rect: 295, 730, 307, 740 ActionDest: 197 Annotation: Subtype: Link Rect: 155, 187, 192, 197 Annotation: Subtype: Link Rect: 59, 161, 96, 172 Annotation: Subtype: Link Rect: 171, 123, 209, 133 Annotation: Subtype: Link Rect: 386, 97, 424, 108 Annotation: Subtype: Link Rect: 371, 71, 409, 82 Annotation: Subtype: Link Rect: 415, 71, 451, 82 Page: Sequence: 13 Annotations: Annotation: Subtype: Link Rect: 335, 731, 372, 742 Annotation: Subtype: Link Rect: 378, 731, 414, 742 Annotation: Subtype: Link Rect: 454, 692, 491, 703 Annotation: Subtype: Link Rect: 59, 655, 96, 665 Annotation: Subtype: Link Rect: 102, 655, 138, 665 Annotation: Subtype: Link Rect: 410, 628, 447, 639 Annotation: Subtype: Link Rect: 493, 603, 530, 614 Annotation: Subtype: Link Rect: 144, 565, 182, 576 Annotation: Subtype: Link Rect: 188, 565, 224, 576 Annotation: Subtype: Link Rect: 131, 527, 168, 537 Annotation: Subtype: Link Rect: 414, 488, 451, 499 Annotation: Subtype: Link Rect: 59, 450, 96, 461 Annotation: Subtype: Link Rect: 174, 412, 211, 422 Annotation: Subtype: Link Rect: 118, 374, 155, 384 Annotation: Subtype: Link Rect: 160, 348, 197, 358 Annotation: Subtype: Link Rect: 203, 348, 239, 358 Annotation: Subtype: Link Rect: 405, 322, 442, 333 Annotation: Subtype: Link Rect: 339, 284, 377, 295 Annotation: Subtype: Link Rect: 95, 259, 133, 269 Annotation: Subtype: Link Rect: 139, 259, 175, 269 Annotation: Subtype: Link Rect: 485, 220, 523, 231 Annotation: Subtype: Link Rect: 446, 194, 484, 205 Annotation: Subtype: Link Rect: 490, 194, 526, 205 Annotation: Subtype: Link Rect: 257, 156, 295, 167 Annotation: Subtype: Link Rect: 301, 156, 337, 167 Checksum: 75be950f Type: CRC32 Checksum: f848b6f13c5f10ae45dde9209034d779 Type: MD5 Checksum: 9e751f5b057eadbc97034c538e7b00aaf226b6e1 Type: SHA-1 Checksum: b693e6f84b667c21dc9254cb834a460b26941f5c70e5b9d53c01ecde674521f2 Type: SHA-256